Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Tags: , , , , ,

Related Post

What can speech tell us about pain?

  • Posted on 26 June, 2025
    Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...
    Read more

    Understanding speech and language in KIF1A-associated neurological disorder

    • Posted on 17 June, 2025
      A new study published in the European Journal of Human Genetics provides the first systematic analysis of speech and language...
      Read more

      Redenlab contributes to position paper on advancing digital healthtechnologies for frontotemporal degeneration

      • Posted on 15 May, 2025
        MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
        Read more